Finoriq research workspace
AIM ImmunoTech Inc. (AIM) SEC Filings & Filing Highlights
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of. Review AIM SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
- Company
- AIM ImmunoTech Inc. (AIM)
- Ticker
- AIM
- Market Cap
- $6.9M
- Latest Price
- $0.2487
- Industry
- Biotech & Pharma
AIM ImmunoTech Inc. (AIM) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for AIM ImmunoTech Inc. (AIM).
| Event | Form | Date |
|---|---|---|
| AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity DeficiencyAIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency | 8-K8.01 | 2026-06-15 |
| AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American RulesAIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules | 8-K8.01 | 2026-06-11 |
| AIM ImmunoTech Inc.: Securities issuanceThe Unregistered Shares, Pre-Funded Warrants, Class J Warrants, and the Placement Agent Warrants will be issued in a private placement purs... | 8-K3.02 | 2026-06-11 |
| Securities Purchase AgreementOn June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with instituti... | 8-K1.01 | 2026-06-11 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-06-10 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.